Interestingly, human DHLs were expected to be highly venetoclax sensitive due to their high expression of BCL-2, however, venetoclax monotherapy has only been tested in patients with relapsed DLBCL, including a limited number of DHL patients, which produced low overall response rates50. Here, BCL2 is linked to diffuse large B-cell lymphoma.